Ironwood Pharmaceuticals, Inc.
A Boston-based biotechnology company that develops and sells medicines for digestive and rare diseases, best known for Linzess, a prescription treatment for chronic constipation and irritable bowel syndrome. It began in 1998 as Microbia, founded by postdocs from a Whitehead Institute lab, and renamed itself Ironwood in 2008 after the long-lived desert tree that shelters other plants — a nod to endurance. Its flagship drug linaclotide was discovered by those same early researchers.
Granted 83.7K · Sold 6.73M
Granted 177.1K
Granted 2.42M · Sold 1.20M
Granted 660.8K · Sold 200.2K
Granted 440.1K · Sold 103.0K
Granted 367.1K · Sold 260.4K
Granted 599.6K · Sold 178.9K
Granted 206.5K · Sold 196.3K
Granted 136.6K · Sold 31.4K
Granted 346.7K · Bought 46.8K · Sold 17.6K
Granted 247.7K · Sold 35.3K
Granted 176.7K · Sold 54.4K
Granted 176.7K · Sold 74.3K
Granted 176.7K · Bought 6.9K
Granted 176.7K
Granted 176.7K · Sold 17.5K
Granted 116.0K
Granted 188.1K · Sold 80.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Denner Alexander JDirector · 6 transactions | — | 18.96M | 83.7K | — | 6.73M |
| Denner Alexander J +1 co-filerDirector, 10% owner, 10% owner · 21 transactions | -1.7% | 16.17M | 177.1K | — | — |
| MCCOURT Thomas AChief Executive Officer, Director · 40 transactions | +182.9% | 1.90M | 2.42M | — | 1.20M |
| Shetzline MichaelSVP, CMO, Head-Res&Drug · 28 transactions | — | 1.18M | 660.8K | — | 200.2K |
| Silver RonaldPFO & PAO · 27 transactions | — | 858.1K | 440.1K | — | 103.0K |
| Currie Mark GDirector · 8 transactions | +18.7% | 676.9K | 367.1K | — | 260.4K |
| John MinardoChief Legal Officer · 19 transactions | +526.5% | 500.5K | 599.6K | — | 178.9K |
| Rickard JasonSVP, Chief Operating Officer · 24 transactions | +4% | 376.3Kas of Mar 2023 | 206.5K | — | 196.3K |
| Gaskins Tammi LChief Commercial Officer · 6 transactions | — | 350.4K | 136.6K | — | 31.4K |
| Emany Sravan KumarSVP, COO and CFO · 12 transactions | — | 309.6Kas of Nov 2024 | 346.7K | 46.8K | 17.6K |
| Martini Gregory S.Chief Financial Officer · 6 transactions | — | 297.2K | 247.7K | — | 35.3K |
| Davis AndrewSVP, Chief Business Officer · 11 transactions | — | 284.7Kas of Nov 2024 | 176.7K | — | 54.4K |
| McHugh JulieDirector · 9 transactions | +83.5% | 272.3K | 176.7K | — | 74.3K |
| Duane Jon RDirector · 6 transactions | +261.6% | 253.8K | 176.7K | 6.9K | — |
| Shepard JayDirector · 5 transactions | +303% | 235.0K | 176.7K | — | — |
| Kessler Marla LDirector · 7 transactions | +226.8% | 229.4K | 176.7K | — | 17.5K |
| Dreyfus AndrewDirector · 6 transactions | +71.3% | 228.3Kas of Jun 2025 | 116.0K | — | — |
| Moukheibir CatherineDirector · 14 transactions | +147.4% | 181.4K | 188.1K | — | 80.0K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -9.13M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.